HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial
Mené en Norvège auprès de 6 000 femmes n'ayant pas participé au dépistage du cancer du col de l'utérus depuis au moins 10 ans (âge : de 35 à 69 ans), cet essai randomisé évalue l'efficacité, du point de vue du taux de participation au dépistage, de trois interventions consistant à envoyer un rappel, un kit d'auto-prélèvement pour test HPV ou une invitation à commander ce kit
Background : Cervical cancer screening participation is suboptimal in most settings. We assessed whether human papillomavirus (HPV) self-sampling may increase screening participation among long-term non-attenders in Norway.
Methods : A pragmatic randomised controlled trial with participation as the primary outcome was initiated in the national cervical screening programme in March 2019. A random sample of 6000 women aged 35–69 years who had not attended screening for at least 10 years were randomised 1:1:1 to receive either (i) a reminder to attend regular screening (control), (ii) an offer to order a self-sampling kit (opt-in) for HPV testing or (iii) a self-sampling kit unsolicited (send-to-all) for HPV testing.
Results : Total participation was 4.8%, 17.0% and 27.7% among control, opt-in and send-to-all (P < 0.0001; participation difference (%) send-to-all vs. control: 22.9 (95%CI: 20.7, 25.2); opt-in vs. control: 12.3 (95%CI: 10.3, 14.2); send-to-all vs. opt-in: 10.7 (95% CI: 8.0, 13.3)). High-risk HPV was detected in 11.5% of self-samples and 9.2% of clinician-collected samples (P = 0.40). Most women (92.5%) who returned a positive self-sample attended the clinic for triage testing. Of the 933 women screened, 33 (3.5%) had CIN2 + (1.1%, 3.7%, 3.8% among control, opt-in, and send-to-all, respectively), and 11 (1.2%) had cervical cancer (0%, 1.2%, 1.3% among control, opt-in, send-to-all, respectively).
Conclusion : Opt-in and send-to-all self-sampling increased screening participation among long-term, higher-risk non-attenders.
Clinical trial registration : ClinicalTrials.gov NCT03873376.
British Journal of Cancer , article en libre accès, 2022